Accueil > International > Génériques > Abbott tue les malades thaïlandaisES : campagne de protestation

Abbott tue les malades thaïlandaisES : campagne de protestation

jeudi 26 avril 2007

Act Up-Paris vous propose de participer à une campagne de protestation contre les actionnaires du laboratoire Abbott. Vous trouverez ici un modèle de lettre à envoyer aux investisseurs du laboratoire, et leurs coordonnées.

Dear Sir, Dear Madam,

You receive this letter because you are a shareholder of Abbott. In a few days, the General Assembly of the group will take place. I’m asking you to do all that you can for the group to change its recent decision about Thailand, and starts again registering new drugs in this country. Abbott’s policy in Thailand will otherwiser put to deaths tens of thousands of patients in Thailand, in a very near future. If you or your company does not clearly oppose this decision, you’ll be responsible of the health degradation and of the death of patients.

In January, Thailand issued compulsory licenses on products whose patent is owned by Abbott. It did so legally, abiding by the international laws on intellectual property. These laws, clearly endorsed by the international community, were passed in a World Trade Organization meeting in 2001. They give the right to any country in the world to produce and/or import generic drugs at a lesser cost in various situations (on of them being a major health crisis). The decision of your group not to provide any new product as a mean of retaliation is then not only scandalous, it is iniquitous.

Among the medicines you’re depriving Thai people from, one of them is an extremely important one for countries with rural and tropical areas like Thailand. Aluvia, a new generation anti retroviral drug, is indeed heat stable and does not need to be refrigerated. It is then vital for many Thai people, a million of whom were HIV-positive in 2005.

Abbott’s recent declaration to offer HIV treatments to some countries will leave our anger unabated. It only provides other evidence that faced to some pressure, you can modify your prices without endangering the financial health of the group. Actually, the results published last week for the first 3 months of 2007 show that it is far from being the case.

Abbott is currently the most hated pharmaceutical firm in the world. It was not given any opportunity to be present at the last HIV International Conference in Toronto, in august 2006. In March, its presentation at the Paris Conference was interrupted by patients. Health professionals around the world have decided not to prescribe any new drug if an important change does not happen in the group’s policy. Abbott’s public image is wasted, and the group is not any longer regarded as a responsible party for both organizations nor for governments.

There is no justification for depriving tens of thousands of patients from drugs that are essential to their life. This is why Act Up-Paris will make your name and that of your group public if you were to approve of the decision of the group on April, 27th. We are determined to identify individually every person that supported the decision, be it passively by just non-opposing to it. Recently, some of its shareholders have criticized Abbott’s decision. They proved that one can be a shareholder and promote ethical practices. It is now your turn. The world is watching you.


Contact des investisseurs d’Abbott

Vous trouverez ci-dessous les emails des principaux investisseurs d’Abbott. Soit nous disposons des adresses emails même, auquel cas vous pouvez envoyer le courrier en le copiant / collant directement dans le corps du message ; soit nous ne disposons que de formulaires en ligne, auquel cas vous remplissez ce formulaire, en faisant attention aux éventuelles restrictions (nombre de caractères, etc.). Des indications pour suivre les liens vous sont données si besoin est.

Si vous n’avez pas le temps de tout faire, merci de privilégier les 5 premiers groupes, qui détiennent le plus de parts.

 1Capital Research & Management Co

 2 Wellington Management Co. LLP

 3 Barclays Global Investors


choisir Media/press et General SSGA Information
choose Media / press and General SSGA Information

 5 Vangard Group Inc

 6 Deutsche Bank Investment Management, Inc.

 7 Jennison Associates LLC

 8 State Farm Insurance Co. Asset Management

 9 Columbia Management Advisors, Inc.
Institutional Clients and Consultants

 10 ClearBridge Advisors
Gerrard Bushell :

 11 BlackRock Advisors, Inc.
Nigel Webb (Head of Corporate Communications) :
Emma Phillips (Media Relations - Europe, Middle East, Africa) :
Anciea Barham (Media Relations - Europe, Middle East, Africa) :
Brian Beades (Media Relations - United States) :

 12 Mellon Capital Management
Scott Ruddick (Managing Director, Business Development) :
Eileen McCarthy (Director, Marketing Communications) :
Jenny Frankowski (Human Resources) :

 13 Van Kampen Investments
Asset Management

 14 TIAA-CREF Asset Management LLC
Chad Peterson (Director, Corporate Media Relations) :
Jennifer L. Compton :

 15 Northern Trust Global Investments
Penelope Biggs (Executive Vice President) :